Загрузка страницы

Cytokine interference in infection

Cytokine interference in infection

Air date: Wednesday, June 12, 2019, 3:00:00 PM

Category: WALS - Wednesday Afternoon Lectures

Runtime: 00:58:35

Description: NIH Director's Wednesday Afternoon Lecture Series

Dr. O'Garra's laboratory studies cells and molecules that control our immune systems to understand how they respond to infections and influence the outcomes and what goes wrong when infections damage healthy cells. For example, some infected individuals are protected while others go on to progress to disease such as tuberculosis (TB), which is caused by infection with Mycobacterium tuberculosis (M. tuberculosis). TB is a major cause of morbidity and mortality worldwide and efforts to control this disease are hampered by difficulties with diagnosis, prevention, and treatment. Most people infected with M. tuberculosis remain asymptomatic or have latent (noninfectious) TB, but they have a 10 percent lifetime risk of developing the active form of the disease.

In 2010, Dr. O'Garra's laboratory identified a gene signature dominated by type I interferon (IFN) inducible genes in the bloodstream of people with TB, which disappears during successful treatment. The lab is also studying the regulation and function of type I IFNs which exacerbate bacterial infections, in part, by inducing a regulatory cytokine called IL-10.

Type I IFNs are cytokines that have been shown for years to be important in the control of viral infections. In experimental models, the lab showed that elevated levels of this cytokine lead to increased TB disease; subsequent studies now provide further knowledge regarding the heterogeneity of this blood signature in some, but not all, asymptomatic TB contacts and how this signature relates to whether they are protected or will develop the disease.

During the lecture, Dr. O'Garra will discuss several potential mechanisms underlying the contribution of type I IFN to the development of TB and diseases caused by other bacterial infections. She will also discuss the impairment of protective responses.

For more information go to https://oir.nih.gov/wals/2018-2019

Author: Anne O'Garra, Ph.D., Associate Research Director and Senior Group Leader, Laboratory of Immunoregulation and Infection, Francis Crick Institute

Permanent link: https://videocast.nih.gov/launch.asp?27613

Видео Cytokine interference in infection канала NIH VideoCast
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
13 июня 2019 г. 20:53:27
00:58:36
Другие видео канала
Gaining New Insights into 'Fundamental Immunology' Using Imaging and ComputationGaining New Insights into 'Fundamental Immunology' Using Imaging and ComputationHeterogeneity of Breast Cancer GenomesHeterogeneity of Breast Cancer GenomesQuality Management in Clinical Research: Preparing for a Successful Quality Visit Part 2Quality Management in Clinical Research: Preparing for a Successful Quality Visit Part 2Data and Safety Monitoring Committees: Trials Needing DSMBs Part 4Data and Safety Monitoring Committees: Trials Needing DSMBs Part 42018 Demystifying Medicine: Compulsive disorders: mechanisms and management2018 Demystifying Medicine: Compulsive disorders: mechanisms and managementAntibodies Against Ebola and Lassa: A Global CollaborationAntibodies Against Ebola and Lassa: A Global CollaborationNeuronal Response to Injury and Stress: Insights from C. elegansNeuronal Response to Injury and Stress: Insights from C. elegansStudy Participant Selection: Example of Participant Selection Part 3Study Participant Selection: Example of Participant Selection Part 3Choosing a Research Question: Developing a Hypothesis and Objectives Part 3Choosing a Research Question: Developing a Hypothesis and Objectives Part 3In Vitro Approaches to Investigate Cell Division and Biological Size ControlIn Vitro Approaches to Investigate Cell Division and Biological Size ControlData Management & Case Report in Clinical Trials: CRF Completion and Query Resolution Part 3Data Management & Case Report in Clinical Trials: CRF Completion and Query Resolution Part 3WALS "Quantitative Proteomics for Understanding Epigenetics Mechanisms"WALS "Quantitative Proteomics for Understanding Epigenetics Mechanisms"Quality of Life: Patient Reported Outcomes: Purpose, Types, Development, and Evaluation Part 1Quality of Life: Patient Reported Outcomes: Purpose, Types, Development, and Evaluation Part 1Medal Winners: How the Vietnam War Launched Nobel CareersMedal Winners: How the Vietnam War Launched Nobel CareersQuality of Life: Interpretation of PRO Scores Part 3Quality of Life: Interpretation of PRO Scores Part 3Developing Protocols & Manuals of Operating Procedures: Informed Consent & Conclusions Part 5Developing Protocols & Manuals of Operating Procedures: Informed Consent & Conclusions Part 5Introduction to Clinical Study Design: Tips for Good Study Design Part 4Introduction to Clinical Study Design: Tips for Good Study Design Part 4Designing Trials Efficiently: Review of Sample Size Considerations Part 2.Designing Trials Efficiently: Review of Sample Size Considerations Part 2.Research With Vulnerable Participants: Vulnerabilities and Safeguards Part 2Research With Vulnerable Participants: Vulnerabilities and Safeguards Part 2Demystifying Medicine 2015 - New Advances in Cancer Diagnosis and Treatment (Immunotoxins)Demystifying Medicine 2015 - New Advances in Cancer Diagnosis and Treatment (Immunotoxins)IPPCR 2019 Overview of Hypothesis Testing Part 4 of 5IPPCR 2019 Overview of Hypothesis Testing Part 4 of 5
Яндекс.Метрика